semaglutide prediabetes weight loss trial progression to diabetes type 2 Approved for Updates in Medicine New Weight Loss Paradigm: Diabetic

Lilly Rx Only NDC 0002-4052-11 Mounjaro (tirzepatide) injection 10 mg/2.4 mL (4.17 mg/mL) ATTENTION: Contains 4 doses of 2.5 mg/0.6 mL 2.4 mL MULTI-DOSE VIAL For Subcutaneous Use Needles and Syringes are not included Dispense enclosed Medication Guide to each patient

Published November 5, 2019

As individuals embark on their weight loss journeys, leveraging available resources and support systems is crucial

Other documented adverse effects include injection site reactions, fatigue, dizziness, and headache

4 Single-dose vials Discard unused portion Lilly PACKAGE LABEL - Zepbound Single-Dose Vial - 10 mg/0.5 mL Dose PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 0002-1340-04 Zepbound (tirzepatide) injection 10 mg/0.5 mL Rx Only For Subcutaneous Use Needles and Syringes are not included Dispense enclosed Medication Guide to each patient

Follow the clinical titration schedule: start at 2.5 mg and increase by 2.5 mg every four weeks